However, clinical studies of broadly acting tyrosine kinase inhibitors for treatment of skin and lung fibrosis have been marred by the development of serious adverse events (67, 68) and EGFR inhibition can paradoxically induce pulmonary fibrosis in patients (69, 70) and mice (11). The gene discussed is EGFR; the disease is pulmonary fibrosis.